Orphans and Incentives Developing Technology to Address Emerging Infections (1997) / Chapter Skim
Currently Skimming:
Introduction
Introduction
Pages 6-8
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 6... ...
The public sector must obtain adequate budgetary allocations for its work, allocations that depend at least in part on the constituencies it can marshal in support of that work; its incentives derive from getting the public health agenda right and responding satisfactorily to the appropriate populations. And, while profitability is not part of its mandate, the public sector is increasingly required to be attentive to costs.
|
From page 7... ...
From this perspective, such technologies can be thought of as "social products," material goods that express important societal values but are nevertheless inefficiently or inadequately represented by market forces. Of these, a significant group-vaccines, contraceptives, pharmaceuticals for managing drug addiction, and diagnostics and therapies for at least some infectious diseases, including sexually transmitted diseases-raises special challenges to decisions about R&D investment.
|
From page 8... ...
They were _ _ =~ ~ · What is the public health agenda for emerging and reemerging infections in those areas where specific responses will be required from industry, and what products are needed? · Of those, which product areas are already a focus of significant industry research and development (R&D)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.